Navigation Links
UV LED therapy shows promising results in preventing focal seizures
Date:1/6/2010

Researchers from the University of Minnesota Medical School discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. During the study, UV light released gamma aminobutyric acid (GABA) from the "caged" compound carbonyl amino butanoic acid (BC204). GABA then decreased the abnormal electrical activity in the CA1 area of the brain. Results of this study have considerable potential in treating focal epilepsy in humans. Details of this study are available in the January 2010 issue of Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Focal (or partial) epilepsy is very common in both adults and can occur in children. It is caused by an abnormality in a localized area of the brain resulting from such conditions as stroke, trauma, or infections. Up to one-third of epileptic patients fail to respond to conventional medical therapies and are subject to toxic effects from antiepileptic drugs (AEDs). While surgery has benefited some patients with focal epilepsy, a substantial number of patients do not experience a complete remission after operation, prompting researchers to investigate alternative treatments.

Steven Rothman, M.D., and colleagues conducted experiments with UV LEDs to control seizure-like activity in rodent brain slices. Population spikes in CA1 (which reflect the discharge of a population of neurons) were elicited by delivering constant current pulses through a microelectrode placed in the CA3 brain area. Researchers induced seizure-like activity by adding the convulsant, 4-aminopyridine (4-AP; 100 M) and removing magnesium from the fluid solution outside the cells. Caged GABA, BC204, was perfused into the preparation for at least 30 minutes prior to the first illumination.

When population spikes were measured (as a reflection of tissue excitability), the research team found that illumination of control slices with up to 200 mA LED current had no effect on peak amplitudes. Addition of BC204 (30 M) and illumination using as little as 50 mA LED current produced a statistically significant reduction of the peak of the population spike. More important, BC204 (10 M) significantly reduced the slice spikes and bursting induced by the 4-AP and low magnesium.

"Our strongly positive results, in an epilepsy model far more severe than the naturally occurring disease, suggest that this technique could translate to human epilepsy," said Dr. Rothman. Researchers believe that a programmable pump could deliver the caged GABA into the subarachnoid space over the epileptic area of the brain. UV LEDs could then be responsively activated to release GABA, using techniques similar to those used for cortical stimulation units that are currently in clinical trials.

The researchers are optimistic that an LED-based implantable device is feasible. "Optical stimulation would be a far more rapid delivery method than any mechanical device for direct administration of drug into the brain and would not subject patients to toxic doses of medication or irreversible brain damage from epilepsy resections," concluded Dr. Rothman.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Sexual function does not continuously decline after radiation therapy treatments for prostate cancer
2. Ring in a Healthy New Year with Massage Therapy in 2010
3. Lithium Beats Valproate for Long-Term Bipolar Therapy
4. Gene Therapy Holds Promise for Emphysema
5. Researchers discover gene therapy to prevent progression of emphysema
6. Psychotherapy offers obesity prevention for at risk teenage girls
7. Rockville and Gaithersburg Now Has Spinal Decompression Therapy
8. HIV Therapy Linked to Fewer Suicides
9. Study finds racial disparities exist in radiation therapy rates for early stage breast cancer
10. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
11. Targeted therapy prolongs life in patients with HER2-positive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... NC (PRWEB) , ... September 20, 2017 , ... ... Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, ... designed presence offers quick and easy access to essential information that offers a ...
(Date:9/20/2017)... GLENDALE, Calif. (PRWEB) , ... September 20, 2017 ... ... 15th year of providing a voice for people who have kidney disease. The ... many writers to share their stories. Entrants needed to meet only one ...
(Date:9/20/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique is excited to ... Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include live ... Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title of ...
(Date:9/20/2017)... ... 20, 2017 , ... As part of The Garland Company, ... redesigned website. The new site – still located at http://www.garlandco.com – ... other industry users that Garland serves. , After an ambitious phase of industry ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going ... receiving positive feedback from customers trying the product for the first time, and others ... was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
Breaking Medicine Technology: